198 related articles for article (PubMed ID: 25104067)
1. A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma.
Wuthrick EJ; Curran WJ; Camphausen K; Lin A; Glass J; Evans J; Andrews DW; Axelrod R; Shi W; Werner-Wasik M; Haacke EM; Hillman GG; Dicker AP
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):369-75. PubMed ID: 25104067
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated Stereotactic Radiotherapy as a Salvage Therapy for Recurrent High-Grade Gliomas: Single-Center Experience.
Reynaud T; Bertaut A; Farah W; Thibouw D; Crehange G; Truc G; Vulquin N
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806498. PubMed ID: 30343637
[TBL] [Abstract][Full Text] [Related]
4. A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies.
Wuthrick EJ; Kamrava M; Curran WJ; Werner-Wasik M; Camphausen KA; Hyslop T; Axelrod R; Andrews DW; Glass J; Machtay M; Dicker AP
Cancer; 2011 Dec; 117(24):5548-59. PubMed ID: 21647871
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas.
Shi W; Palmer JD; Werner-Wasik M; Andrews DW; Evans JJ; Glass J; Kim L; Bar-Ad V; Judy K; Farrell C; Simone N; Liu H; Dicker AP; Lawrence YR
J Neurooncol; 2016 May; 127(3):535-9. PubMed ID: 26821711
[TBL] [Abstract][Full Text] [Related]
6. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
[TBL] [Abstract][Full Text] [Related]
7. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.
Clarke J; Neil E; Terziev R; Gutin P; Barani I; Kaley T; Lassman AB; Chan TA; Yamada J; DeAngelis L; Ballangrud A; Young R; Panageas KS; Beal K; Omuro A
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):797-804. PubMed ID: 28870792
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
Reardon DA; Vredenburgh JJ; Coan A; Desjardins A; Peters KB; Gururangan S; Sathornsumetee S; Rich JN; Herndon JE; Friedman HS
J Neurooncol; 2011 Dec; 105(3):621-7. PubMed ID: 21744079
[TBL] [Abstract][Full Text] [Related]
9. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.
Cabrera AR; Cuneo KC; Desjardins A; Sampson JH; McSherry F; Herndon JE; Peters KB; Allen K; Hoang JK; Chang Z; Craciunescu O; Vredenburgh JJ; Friedman HS; Kirkpatrick JP
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):873-9. PubMed ID: 23725997
[TBL] [Abstract][Full Text] [Related]
10. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma.
Hudes RS; Corn BW; Werner-Wasik M; Andrews D; Rosenstock J; Thoron L; Downes B; Curran WJ
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):293-8. PubMed ID: 10030252
[TBL] [Abstract][Full Text] [Related]
11. Irradiation and bevacizumab in high-grade glioma retreatment settings.
Niyazi M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; Geisler J; la Fougère C; Ertl L; Linn J; Siefert A; Belka C
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):67-76. PubMed ID: 21030162
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
Den RB; Kamrava M; Sheng Z; Werner-Wasik M; Dougherty E; Marinucchi M; Lawrence YR; Hegarty S; Hyslop T; Andrews DW; Glass J; Friedman DP; Green MR; Camphausen K; Dicker AP
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):321-8. PubMed ID: 22687197
[TBL] [Abstract][Full Text] [Related]
13. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.
Shapiro LQ; Beal K; Goenka A; Karimi S; Iwamoto FM; Yamada Y; Zhang Z; Lassman AB; Abrey LE; Gutin PH
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):636-42. PubMed ID: 22765876
[TBL] [Abstract][Full Text] [Related]
14. Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.
Combs SE; Bischof M; Welzel T; Hof H; Oertel S; Debus J; Schulz-Ertner D
J Neurooncol; 2008 Sep; 89(2):205-10. PubMed ID: 18461281
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience.
Guan Y; Xiong J; Pan M; Shi W; Li J; Zhu H; Gong X; Li C; Mei G; Liu X; Pan L; Dai J; Wang Y; Wang E; Wang X
BMC Cancer; 2021 Feb; 21(1):123. PubMed ID: 33546642
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Fields EC; Damek D; Gaspar LE; Liu AK; Kavanagh BD; Waziri A; Lillehei K; Chen C
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):51-7. PubMed ID: 21035955
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.
Gutin PH; Iwamoto FM; Beal K; Mohile NA; Karimi S; Hou BL; Lymberis S; Yamada Y; Chang J; Abrey LE
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):156-63. PubMed ID: 19167838
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy.
Baumann KH; du Bois A; Meier W; Rau J; Wimberger P; Sehouli J; Kurzeder C; Hilpert F; Hasenburg A; Canzler U; Hanker LC; Hillemanns P; Richter B; Wollschlaeger K; Dewitz T; Bauerschlag D; Wagner U
Ann Oncol; 2012 Sep; 23(9):2265-2271. PubMed ID: 22377563
[TBL] [Abstract][Full Text] [Related]
19. Angiogenic blockade and radiotherapy in hepatocellular carcinoma.
Chi KH; Liao CS; Chang CC; Ko HL; Tsang YW; Yang KC; Mehta MP
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):188-93. PubMed ID: 20133077
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1-3 newly diagnosed brain metastases.
Ahluwalia MS; Chao ST; Parsons MW; Suh JH; Wang D; Mikkelsen T; Brewer CJ; Smolenski KN; Schilero C; Rump M; Elson P; Angelov L; Barnett GH; Vogelbaum MA; Weil RJ; Peereboom DM
J Neurooncol; 2015 Sep; 124(3):485-91. PubMed ID: 26245136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
